sildenafil vs Udenafil

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline

sildenafil · Revatio

Marketed by Viatris and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Partial signal

NCT00644605 · Phase 3 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: April 2028 · NCT07824674 (registry estimate)

Reported efficacy

Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test). (Week 12): The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). (met)

Result source: NCT00644605

Udenafil · Zydena

Marketed by Dong-A ST and partners

Phase 2/3 in Pulmonary Arterial Hypertensionsmall molecule
Weak signal

NCT02304198 · Phase 2/3 · completed

The study was an open-label, single-group continuation of the randomized DA8159_PAH_II trial, with 59 participants and no concurrent placebo or active comparator. Its registered primary outcome on ClinicalTrials.gov is "Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Udenafil: no structured comparison results are available for Pulmonary Arterial Hypertension.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

sildenafil

EQ-5D Utility 0.0473 score @ 65wk
absolute change · score
No placebo or comparator arm
NCT00159861 · Phase 3
show 2 more results
0.0483 score @ 117wk
NCT00159861 · Phase 3
0.077 score @ 169wk
NCT00159861 · Phase 3
EQ-5D VAS 12.8 score @ 65wk
absolute change · score
No placebo or comparator arm
NCT00159861 · Phase 3
show 2 more results
11.2 score @ 117wk
NCT00159861 · Phase 3
11.5 score @ 169wk
NCT00159861 · Phase 3
Borg Dyspnea 0 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT00159861 · Phase 3
show 18 more results
0 score @ 8wk
NCT00159861 · Phase 3
0 score @ 12wk
NCT00159861 · Phase 3
0 score @ 16wk
NCT00159861 · Phase 3
0 score @ 20wk
NCT00159861 · Phase 3
0 score @ 24wk
NCT00159861 · Phase 3
0 score @ 39wk
NCT00159861 · Phase 3
0 score @ 52wk
NCT00159861 · Phase 3
0 score @ 65wk
NCT00159861 · Phase 3
0 score @ 78wk
NCT00159861 · Phase 3
0 score @ 91wk
NCT00159861 · Phase 3
0 score @ 104wk
NCT00159861 · Phase 3
0 score @ 117wk
NCT00159861 · Phase 3
0 score @ 130wk
NCT00159861 · Phase 3
0 score @ 143wk
NCT00159861 · Phase 3
0 score @ 156wk
NCT00159861 · Phase 3
-0.84 score @ 8wk
NCT00454207 · Phase 3 · registry result, not featured evidence
-0.95 score @ 12wk
NCT00454207 · Phase 3 · registry result, not featured evidence
0.33 score @ 12wk
NCT00454207 · Phase 3 · registry result, not featured evidence
Peak VO2 6.44% (n=24) vs 0.53% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 5 more results
13.4% (n=26) vs 0.53% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
10.58% (n=27) vs 0.53% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
5.43% (n=23) vs 2.81% (n=24) placebo @ 16wkLow Dose
NCT00159913 · Phase 3
15.66% (n=23) vs 2.81% (n=24) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
9.34% (n=27) vs 2.81% (n=24) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
mPAP 0.9 vs -0.4 placebo mmHg @ 16wkLow Dose
absolute change · mmHg
NCT00159913 · Phase 3
show 2 more results
-3.9 vs -0.4 placebo mmHg @ 16wkMedium Dose
NCT00159913 · Phase 3
-7.4 vs -0.4 placebo mmHg @ 16wkHigh Dose
NCT00159913 · Phase 3
PVRI 0.1 vs 1.6 placebo wood units. m2 @ 16wkLow Dose
absolute change · wood units. m2
NCT00159913 · Phase 3
show 2 more results
-2.9 vs 1.6 placebo wood units. m2 @ 16wkMedium Dose
NCT00159913 · Phase 3
-5.1 vs 1.6 placebo wood units. m2 @ 16wkHigh Dose
NCT00159913 · Phase 3
RER 0% (n=24) vs -0.03% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 2 more results
-0.05% (n=26) vs -0.03% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
-0.02% (n=27) vs -0.03% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
Time to Max VO2 64.83% (n=24) vs 8.84% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 2 more results
64.42% (n=26) vs 8.84% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
31.33% (n=27) vs 8.84% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
Pulmonary Vascular Resistance -0.1 vs 0.1 placebo wood units @ 16wkLow Dose
absolute change · wood units
NCT00159913 · Phase 3
show 2 more results
-3.3 vs 0.1 placebo wood units @ 16wkMedium Dose
NCT00159913 · Phase 3
-5.2 vs 0.1 placebo wood units @ 16wkHigh Dose
NCT00159913 · Phase 3
Cardiac Index Change L/Min M2 0.2 vs -0.6 placebo m @ 16wkLow Dose
absolute change · m
NCT00159913 · Phase 3
show 2 more results
0.02 vs -0.6 placebo m @ 16wkMedium Dose
NCT00159913 · Phase 3
0.24 vs -0.6 placebo m @ 16wkHigh Dose
NCT00159913 · Phase 3
Right Atrial Pressure 7.92 vs 8.11 placebo mmHg @ 16wkLow Dose
absolute change · mmHg
NCT00159913 · Phase 3
show 2 more results
8.05 vs 8.11 placebo mmHg @ 16wkMedium Dose
NCT00159913 · Phase 3
7.75 vs 8.11 placebo mmHg @ 16wkHigh Dose
NCT00159913 · Phase 3
CHQ-PF28, Physical 14 vs 8.3 placebo score @ 16wkLow Dose
absolute change · score
NCT00159913 · Phase 3
show 2 more results
9.8 vs 8.3 placebo score @ 16wkMedium Dose
NCT00159913 · Phase 3
5.9 vs 8.3 placebo score @ 16wkHigh Dose
NCT00159913 · Phase 3

+ 51 further endpoints in the CSV export.

Available safety results

sildenafil

Dropout rate
—
NCT00159861 · Phase 3
show 17 more results
2.6%High Dose
NCT00159913 · Phase 3
4.8%Low Dose
NCT00159913 · Phase 3
0%Medium Dose
NCT00159913 · Phase 3
52.2%high dose
NCT00159874 · Phase 3
46.2%low dose
NCT00159874 · Phase 3
42.1%medium dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
55.8%high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
47.6%low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
54.5%medium dose
NCT00159874 · Phase 3
14%
NCT00323297 · Phase 4
50%
NCT01642407 · Phase 4 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00454207 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—
NCT00159861 · Phase 3
show 17 more results
1.3%High Dose
NCT00159913 · Phase 3
2.4%Low Dose
NCT00159913 · Phase 3
0%Medium Dose
NCT00159913 · Phase 3
8.7%high dose
NCT00159874 · Phase 3
7.7%low dose
NCT00159874 · Phase 3
5.3%medium dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
6.5%high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
4.8%low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
3.6%medium dose
NCT00159874 · Phase 3
4%
NCT00323297 · Phase 4
—
NCT01642407 · Phase 4 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00454207 · Phase 3 · registry result, not featured evidence
Serious AEs
77.6%
NCT00159861 · Phase 3
show 17 more results
—High Dose
NCT00159913 · Phase 3
—Low Dose
NCT00159913 · Phase 3
—Medium Dose
NCT00159913 · Phase 3
—high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
48%high dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
25.5%low dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
50%medium dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
44%
NCT00323297 · Phase 4
0%
NCT01642407 · Phase 4 · registry result, not featured evidence
5.6%400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
10.5%200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
15.9%
NCT00454207 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
headache 67.9% (placebo 18.8%)
diarrhoea 47.8% (placebo 31.3%)
nausea 47% (placebo 25%)
NCT00159861 · Phase 3
show 11 more results
High Dose
headache 15.6% (placebo 13.3%)
vomiting 14.3% (placebo 6.7%)
pyrexia 10.4% (placebo 1.7%)
NCT00159913 · Phase 3
Low Dose
headache 11.9% (placebo 13.3%)
upper respiratory tract infection 9.5% (placebo 6.7%)
nasopharyngitis 7.1% (placebo 6.7%)
NCT00159913 · Phase 3
Medium Dose
pyrexia 14.5% (placebo 1.7%)
upper respiratory tract infection 14.5% (placebo 6.7%)
headache 10.9% (placebo 13.3%)
NCT00159913 · Phase 3
high dose
upper respiratory tract infection 37%
headache 26%
vomiting 24%
NCT00159874 · Phase 3
low dose
headache 32.7%
pharyngitis 29.1%
nasopharyngitis 27.3%
NCT00159874 · Phase 3
medium dose
upper respiratory tract infection 29.7%
headache 24.3%
bronchitis 21.6%
NCT00159874 · Phase 3
diarrhoea 14% (placebo 9.4%)
headache 14% (placebo 13.2%)
oedema peripheral 14% (placebo 15.1%)
NCT00323297 · Phase 4
bronchitis 50%
nasopharyngitis 50%
upper respiratory tract infection 50%
NCT01642407 · Phase 4 · registry result, not featured evidence
400 mg/Day
vomiting 22.2%
anaemia 16.7%
blood potassium decreased 16.7%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
200 mg/Day
diarrhoea 26.3%
nausea 21.1%
back pain 10.5%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 38.6%
headache 25%
flushing 22.7%
NCT00454207 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: sildenafil's landscape · Udenafil's landscape